BDSI is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies for the treatment of debilitating chronic conditions.
Business Model:
Revenue: $166.7M
Employees: 51-200
BDSI was acquired by
Collegium Pharmaceutical.
The acquisition happend on 2022-02-14.
Details of the transaction were not public
Address: 4131 Parklake Avenue
City: Raleigh
State: NC
Zip: 27612
Country: US
BDSI is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies for the treatment of debilitating chronic conditions.
Contact Phone:
+19195829050
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
8/2/2002
Ticker Symbol:
BDSI
Amount Raised:
$11M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2018 | Post-IPO Equity | 1 | $50M |
Broadfin Capital Broadfin Capital Broadfin Capital Broadfin Capital |
2/2017 | Post-IPO Debt | 1 | - |
CRG CRG CRG CRG |
11/2012 | Post-IPO Equity | $40M | 6/2015 | Post-IPO Debt | 1 | $20.7M |
MidCap Financial MidCap Financial |
7/2013 | Post-IPO Debt | $20M | 2/2014 | Post-IPO Equity | 1 | $60M |
Federated Kaufmann Fund Federated Kaufmann Fund |
2/2017 | Post-IPO Debt | $45M |
CRG LP |
5/2015 | Post-IPO Debt | $20.7M | 5/2019 | Post-IPO Debt | $0 |
BioPharma Credit BioPharma Credit |
5/2019 | Post-IPO Debt | 1 | $60M |
BioPharma Credit BioPharma Credit |
2/2017 | Post-IPO Debt | 1 | - |
CRG CRG CRG CRG |
---|
Announced Date | Name | Price |
---|---|---|
8/2004 | Arius Pharmaceuticals |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|